Back to News
Market Impact: 0.34

SpaceX stock: Oppenheimer says it's 'undervalued' at $135

IPOs & SPACsAnalyst InsightsCompany FundamentalsTechnology & InnovationPrivate Markets & Venture

Oppenheimer initiated coverage of SpaceX ahead of its Nasdaq debut with an Outperform rating and a $190 price target, implying about 41% upside. The call suggests a market cap of roughly $2.5 trillion within 12 to 18 months, underscoring strong bullish sentiment around the listing. The news is relevant for SpaceX and the IPO market, but broader market impact should be limited.

Analysis

OPY is the cleanest near-term beneficiary, but not because it owns a direct revenue stream from this event; the value is in signaling. A credible first-mover initiation on a highly desired private asset can pull forward client engagement, syndicate relevance, and underwriting mandates across the late-stage/pre-IPO complex, especially if competitors are still waiting on secondary market structure to settle. That should modestly improve the economics of any brokerage with research distribution, capital markets, or private shares facilitation capabilities, even if the immediate P&L impact is small.

The more important second-order effect is on the broader private-market ecosystem: the pricing benchmark now moves from occasional private financings to public tape comparables, forcing late-stage investors, crossover funds, and employee sellers to re-mark expectations quickly. If the stock stabilizes above the initial guide, it will embolden other brokers to publish aggressive targets, increasing attention flow and potentially compressing the discount at which private shares trade relative to listed equivalents. That can be supportive for NDAQ in the sense of heightened issuance and trading activity, but the bigger winner is likely platforms and intermediaries that monetize volatility, not the exchange itself.

The contrarian risk is that a $2.5T narrative is too large too fast: even if the business deserves a premium multiple, the market may treat the first target as a peak extrapolation point rather than a base case. In the first days to weeks, the setup is vulnerable to rumor-driven chop, early employee/VC selling, and any mismatch between implied valuation and the actual free float. If the stock trades well but cannot hold the high-90s/low-100s equivalent of the guide, sentiment could reverse sharply within 1-2 months as the market reprices the growth runway from story to execution.

Best trade expression is to stay selective: own OPY tactically into the launch window as a beneficiary of elevated research demand, but treat it as a short-duration catalyst trade, not a structural re-rate. For NDAQ, the cleaner angle is a vol/liquidity capture trade around the debut period rather than a directional equity bet; the exchange benefit is real but likely modest and already partly anticipated.